Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksETX.L Share News (ETX)

  • There is currently no data for ETX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Monday broker round-up - UPDATE

Mon, 22nd Oct 2012 08:19

888 Holdings: Morgan Stanley ups target from 125p to 130p, overweight rating kept.Aggreko: Jefferies cuts target from 2,800p to 2,535p, buy rating kept; HSBC downgrades to underweight, target cut from 2,350p to 1,750p; JPMorgan Cazenove cuts target from 2,360p to 2,165p, neutral rating kept; Barclays Capital cuts target from 2,550p to 2,360p, overweight rating kept.Alliance Pharma: Investec ups target from 28p to 28.7p, hold rating kept.ASOS: Investec raises target from 2,450p to 2,700p, buy rating kept.Bunzl: Jefferies ups target from 860p to 880p, underperform rating kept.Circle Oil: Investec keeps buy rating and 80p target.Darty: AlphaValue upgrades from reduce to add.Debenhams: Investec raises target from 114p to 122p, buy rating kept.Devro: Panmure Gordon keeps hold rating and 320p target; Investec keeps buy rating and 355p target.Dixons: AlphaValue upgrades from add to buy.e-Therapeutics: Panmure Gordon cuts target from 76p to 73p, buy rating kept.Fidessa: Merchant Securities cuts target from 1,700p to 1,510p, buy rating kept; Jefferies keeps hold rating and 1,510p target; Investec cuts target from 1,230p to 1,110p, sell rating kept.Hikma Pharmaceuticals: UBS downgrades neutral to sell, 755p unchanged.Jardine Lloyd Thompson: Investec ups target from 692p to 758p, hold rating kept.JD Sports: Seymour Pierce upgrades from hold to buy, target lifted from 800p to 1,000p.Marks & Spencer: Investec keeps sell rating and 275p target.Max Petroleum: Merchant Securities increases target from 4.0p to 4.4p, hold rating kept.Mothercare: HSBC ups target from 180p to 295p, neutral rating kept.Next: Investec keeps hold rating and 3,680p target.Ophir Energy: Jefferies maintains buy rating and 800p target.Paragon Group of Companies: UBS raises target from 254p to 262p, buy rating kept.Petrofac: Liberum Capital downgrades to hold, 1,703p target kept.Provident Financial: JPMorgan Cazenove lifts target from 1,500p to 1,626p, overweight rating kept.RBS: Investec downgrades from hold to sell, 255p target kept.Reckitt Benckiser: Investec maintains hold rating and 3,600p target.Senior: Jefferies maintains buy rating and 223p target; Investec cuts target from 250p to 225p, buy rating kept.Spectris: Panmure Gordon downgrades from buy to hold; Investec upgrades to buy.Spirit Pub: Morgan Stanley ups target from 40p to 55p, underweight rating kept.St James's Place: JPMorgan Cazenove raises target from 417p to 435p, overweight rating kept.Travis Perkins: AlphaValue upgrades from reduce to add.Vodafone: Liberum Capital cuts target from 210p to 205p, buy rating kept.Weir: Panmure Gordon downgrades from buy to hold.Whitbread: Investec keeps sell rating and 1,650p target.William Hill: Barclays Capital ups target from 270p to 280p, underweight rating kept.BC
More News
20 Mar 2018 16:14

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 21 March KingfisherFull Year ResultsAlpha FXFull Year In SportFull 22

Read more
9 Jan 2017 08:49

E-Therapeutics Hires Amgen Director As New Chief Executive

Read more
6 Oct 2016 11:23

DIRECTOR DEALINGS: e-Therapeutics Non-Executive Acquires Shares

Read more
14 Sep 2016 11:23

e-Therapeutics Development Director Steve Self To Step Down

Read more
13 Jul 2016 09:13

E-Therapeutics Chairman Takes On Executive Duties As CEO Steps Down

Read more
1 Jun 2016 08:03

e-Therapeutics Offer For Searchbolt Now Wholly Unconditional

Read more
25 May 2016 08:18

e-Therapeutics Focused On Validation Of Drug Discovery Platform

Read more
18 May 2016 15:05

AGM, EGM Calendar - Week Ahead

Read more
12 May 2016 11:13

DIRECTOR DEALINGS: E-Therapeutics Non-Executive Acquires Shares

Read more
11 May 2016 09:06

e-Therapeutics To Buy Searchbolt For GBP2.3 Million (ALLISS)

Read more
22 Mar 2016 11:40

E-Therapeutics Loss Widens As Active Projects Increase

Read more
15 Mar 2016 16:15

Earnings, Trading Statements Calendar - Week Ahead

Read more
15 Feb 2016 10:43

WINNERS & LOSERS SUMMARY: Reckitt Benckiser Results Please Investors

Read more
15 Feb 2016 09:45

E-Therapeutics depression drug trials miss targets

(ShareCast News) - Drug trials results for e-Therapeutics' depression treatment were not as successful as had been hoped, sending shares in the company sharply lower. Phase IIb clinical trials of the company's ETS6103 product did not achieve the aim of matching the efficacy of existing tricyclic ant

Read more
15 Feb 2016 08:20

E-Therapeutics Shares Drop As ETS6103 Trials Miss Primary Endpoint

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.